ProMIS Neurosciences claimed further results of previously claimed Preclinical program for Alzheimer’s Disease

ProMIS Neurosciences committed to the discovery and development of precision treatments for neurodegenerative diseases, announced further results of its previously announced and ongoing preclinical program for Alzheimer’s disease (AD). Lead product candidate for AD, PMN310 exhibited higher binding to the neurotoxic oligomer-enriched fraction of amyloid beta (Aβ) in brain extract from eight confirmed AD brains as compared to aducanumab (Biogen).

ProMIS Executive Chairman, Eugene Williams, stated: “We set out to design an improved antibody inspired by the initial successful clinical results of aducanumab  announced in Dec 2014. We recently reported greater selectivity of PMN310 for Aβ oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab. ProMIS also recently announced that PMN310 shows a lack of binding to plaque in and around blood vessels in the brain, thereby supporting the potential for lower risk of brain swelling and possibility of higher dosing with PMN310.”

ProMIS isolated the soluble low molecular weight (LMW) fraction of brain material from eight AD brains expected to contain dodecamers, tetramers and dimers. Binding by aducanumab, bapineuzumab and humanized PMN310 to the toxic oligomer fraction from these brains was assessed by surface plasmon resonance (SPR). SPR is a highly sensitive technique to detect binding interactions. In the SPR study outlined above, the test antibody therapeutics (bapineuzumab, aducanumab and humanized PMN310) were each immobilized on an SPR sensor chip.